105.27
0.59%
-0.63
After Hours:
105.80
0.53
+0.50%
Abbott Laboratories stock is currently priced at $105.27, with a 24-hour trading volume of 7.19M.
It has seen a -0.59% decreased in the last 24 hours and a -6.38% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $106.3 pivot point. If it approaches the $103.9 support level, significant changes may occur.
Abbott Laboratories Stock (ABT) Financials Data
Abbott Laboratories (ABT) Revenue 2024
ABT reported a revenue (TTM) of $40.11 billion for the quarter ending December 31, 2023, a -8.12% decline year-over-year.
Abbott Laboratories (ABT) Net Income 2024
ABT net income (TTM) was $5.72 billion for the quarter ending December 31, 2023, a -17.45% decrease year-over-year.
Abbott Laboratories (ABT) Cash Flow 2024
ABT recorded a free cash flow (TTM) of $5.06 billion for the quarter ending December 31, 2023, a -35.17% decrease year-over-year.
Abbott Laboratories (ABT) Earnings per Share 2024
ABT earnings per share (TTM) was $3.26 for the quarter ending December 31, 2023, a -16.62% decline year-over-year.
Abbott Laboratories Stock (ABT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Salvadori Daniel Gesua Sive | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
963 |
114,116 |
125,697 |
ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
853 |
101,080 |
184,806 |
Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
801 |
94,918 |
62,968 |
Earnhardt Lisa D | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
694 |
82,239 |
84,314 |
Moreland Mary K | EXECUTIVE VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
676 |
80,106 |
91,260 |
MCCOY JOHN A. JR. | VICE PRESIDENT |
Mar 01 '24 |
Sale |
118.50 |
472 |
55,932 |
18,760 |
Wainer Andrea F | EXECUTIVE VICE PRESIDENT |
Feb 23 '24 |
Option Exercise |
59.94 |
12,500 |
749,250 |
91,204 |
Wainer Andrea F | EXECUTIVE VICE PRESIDENT |
Feb 23 '24 |
Sale |
120.00 |
12,500 |
1,500,000 |
78,704 |
Wainer Andrea F | EXECUTIVE VICE PRESIDENT |
Jan 29 '24 |
Option Exercise |
50.80 |
42,500 |
2,158,950 |
90,027 |
Wainer Andrea F | EXECUTIVE VICE PRESIDENT |
Jan 29 '24 |
Sale |
112.50 |
42,500 |
4,781,250 |
65,027 |
Abbott Laboratories Stock (ABT) Latest News
Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What's Driving Markets Wednesday?
Benzinga
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
The Motley Fool
Q1 Earnings Review
Zacks Investment Research
Markets Try to Shake Off April Blues
Zacks Investment Research
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
Zacks Investment Research
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings
Benzinga
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Cap:
|
Volume (24h):